Annovis Bio阿尔茨海默病三期临床试验完成入组;顶线数据及申报预计2027年完成

美股速递
Aug 25

Annovis Bio(股票代码:ANVS)宣布,其针对阿尔茨海默病的三期临床试验已圆满完成患者入组工作。这一关键节点标志着该研究项目正式步入下一阶段。根据公司规划,顶线数据读出及相关监管申报预计将在2027年实现。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10